Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3636 | Sirukumab Wiki | 0.45 |
| drug1966 | Interferon-ß-1a Wiki | 0.45 |
| drug648 | Brief Behavioral Activation Treatment Wiki | 0.45 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3528 | Sampling of SARS-CoV-2 RNA from nasopharyngeal swab specimen or saliva collected via Salivette Cortisol Wiki | 0.45 |
| drug702 | CHLORPROMAZINE (CPZ) Wiki | 0.45 |
| drug674 | C2Rx Wiki | 0.45 |
| drug2827 | Pathways for Parents after Incarceration Wiki | 0.45 |
| drug3384 | Rivaroxaban Wiki | 0.20 |
| drug2916 | Placebo Wiki | 0.04 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D001238 | Asphyxia Neonatorum NIH | 0.45 |
| D011654 | Pulmonary Edema NIH | 0.26 |
| D003866 | Depressive Disorder NIH | 0.08 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0012768 | Neonatal asphyxia HPO | 0.45 |
| HP:0100598 | Pulmonary edema HPO | 0.26 |
| HP:0000716 | Depressivity HPO | 0.08 |
Navigate: Correlations HPO
There are 5 clinical trials
This study evaluates the effects of the addition of chlorpromazine to the standard therapeutic protocol in COVID-19 patients hospitalized for respiratory symptom management (score 3-5 WHO Ordinal Scale for Clinical Improvement).
Description: The primary endpoint is the time to response (TTR) in days, from randomization to 28th day. By response to treatment is meant the reduction of at least one severity level on the World Health Organization Ordinal Scale for Clinical Improvement (WHO-OSCI) The WHO-OSCI is an ordinal scale of 9 severity levels (from 0 to 8) for COVID-19. This scale was established by the WHO, which recommends its use for any therapeutic study on COVID-19. This will be a continuous outcome defined by the amount of time between randomization to the first response. This will be treated as a time-to-event with possible censoring.
Measure: Time To Response (TTR) Time: 28 daysDescription: Response rate regarding the World Health Organization Ordinal Scale for Clinical Improvement (WHO-OSCI). This will be a binary outcome defined by clinical conditions improvement assessment from randomization to 28th Day, by the response to treatment is meant the reduction of at least one severity level on the World Health Organization Ordinal Scale for Clinical Improvement (WHO-OSCI).
Measure: Objective Response Rate (ORR) Time: 28 days from randomizationDescription: All-cause mortality rates at Day 28th after randomization
Measure: All-cause mortality Time: 28 days after randomizationDescription: This will be a continuous outcome defined by the amount of time in days between randomization and the hospital discharge
Measure: Duration in days required for hospital discharge Time: 28 days after randomizationDescription: This will be a continuous outcome defined by the amount of time in days between randomization and National Early Warning Score ≤ 2 maintained for almost 24 hours The National Early Warning Score (NEWS) is a score used in the ICU to evaluate the overall severity of the clinical condition of a patient.
Measure: Duration in days required for National Early Warning Score ≤ 2 maintained 24 hours Time: 28 days after randomizationDescription: This will be a continuous outcome defined by the amount of time in days without oxygen therapy
Measure: Number of days without oxygen therapy Time: 28 days after randomizationDescription: Number of clinical conditions that need a prescription for Oxygen therapy, NIV or high flow oxygen therapy
Measure: Incidence of oxygen use, NIV or high flow oxygen therapy Time: 28 days after randomizationDescription: This will be a continuous outcome defined by the amount of time in days with oxygen therapy, NIV, or high flow oxygen therapy.
Measure: Duration in days of oxygen prescription, NIV or high flow oxygen therapy Time: 28 days after randomizationDescription: Rate of patients positive for SARS-CoV-2 PCR on a nasopharyngeal sample (biobank sample) (day 7) This will be a binary outcome defined by positive or negative results at SARS-CoV-2 PCR on a nasopharyngeal sample
Measure: Biochemical response: rate of patients positive for SARS-CoV-2 PCR on a nasopharyngeal sample Time: day 7 from randomizationDescription: This will be a quantitative variable. Biobank sample at day 7
Measure: Biochemical response: viral load of SARS-CoV-2 on a nasopharyngeal sample Time: day 7 from randomizationDescription: This will be a quantitative variable. Biobank blood sample at D3, D5, D7 then, if hospitalization continues blood sample at D14, D21, and D28
Measure: Biochemical response: serum viral load of SARS-CoV-2 Time: day: 3,5,7,14,21,28Description: This will be a quantitative variable. Biobank blood sample at D3, D5, D7 then, if hospitalization continues blood sample at D14, D21, and D28
Measure: Biochemical response: C-reactive protein (CRP) Time: day: 3,5,7,14,21,28Description: This will be a quantitative variable. Biobank blood sample at D3, D5, D7 then, if hospitalization continues blood sample at D14, D21, and D28
Measure: Biochemical response: blood test for lymphocytes (lymphopenia) Time: day: 3,5,7,14,21,28Description: Extension score of parenchymal involvement in thoracic computed tomography (CT) (D7)
Measure: Parenchymal involvement (chest CT) Time: day 7Description: Rates of serious adverse events
Measure: Define the optimal dose of CPZ and its tolerance: rates of serious adverse events Time: 28 daysDescription: Rates of non-serious side effects
Measure: Define the optimal dose of CPZ and its tolerance: rates of non-serious side effects Time: 28 daysDescription: Global Anxiety - Visual Analog Scale (GA-VAS) is a scale for the assessment of anxiety. The 100 mm GA-VAS varies from minimum (not at all anxious) to maximum (Extremely anxious). This will be a quantitative variable, the distance from the left edge of the line to the mark placed by the patient is measured to the nearest millimeter and used in analyses as the patient's GA-VAS score.
Measure: Define the optimal dose of CPZ and its tolerance: anxiety assessment on Global Anxiety - Visual Analog Scale (GA-VAS) Time: 28 daysDescription: Rates of drug discontinuation in all causes under study
Measure: Define the optimal dose of CPZ and its tolerance: Rates of drug discontinuation Time: 28 daysDescription: NFS, TP TCA, blood ionogram and hepatic check-up, glycemia. This will be a quantitative variable. Biobank blood sample at D3, D5, D7 then, if hospitalization continues blood sample at D14, D21, and D28
Measure: Define the optimal dose of CPZ and its tolerance: biological anomalies Time: day: 3,5,7,14,21,28Description: Rate of patients with ECG abnormalities at D3, D5, D7 then, if hospitalization continues blood sample at D14, D21, and D28
Measure: Define the optimal dose of CPZ and its tolerance: ECG abnormalities Time: day: 3,5,7,14,21,28Description: plasma CPK assessment at D3, D5, D7 then, if hospitalization continues blood sample at D14, D21, and D28
Measure: Define the optimal dose of CPZ and its tolerance: plasma CPK assessment Time: day: 3,5,7,14,21,28Description: Plasma CPZ assessment at D3, D5, D7 then, if hospitalization continues blood sample at D14, D21, and D28
Measure: Define the optimal dose of CPZ and its tolerance:plasma CPZ assessment Time: day: 3,5,7,14,21,28Description: CPZ dosages administered
Measure: Define the optimal dose of CPZ and its tolerance: CPZ dose administered Time: 28 daysDescription: Biobank by blood samples of 20 ml per patient (on D1, D3, D5, D7, then, if continued hospitalization at D14, D21, D28) allowing, in addition to viral markers:Cytokine and lymphocyte profile assays in flow cytometry: IL-2, IL-6, IL-7, IL-10, GCSF, IP10, MCP1, M1P1A and TNF-alfa, FACs CD3, CD4, CD8, CD38
Measure: Evaluate the biological parameters to treatment response (biobank constitution for carrying out cytokine assays, lymphocyte profiles in flow cytometry and additional explorations according to the evolution of knowledge on COVID-19) Time: day: 1, 3,5,7,14,21,28The purpose of this study is to evaluate the clinical response of sirukumab (administered as a single intravenous dose) plus standard of care (SOC) compared to placebo plus SOC in COVID-19.
Description: Time to improvement is defined as an improvement of at least 2 categories relative to baseline on the 6-point ordinal clinical recovery scale. The 6-point ordinal clinical recovery scale provides 6 mutually exclusive conditions ordered from best to worst, and the score reflects the participant's worst situation on the day assessed. The ordinal clinical recovery scale categories are : not hospitalized (category 1); Hospitalization; not requiring supplemental oxygen (category 2); hospitalized, requiring low flow supplemental oxygen (category 3); hospitalized, on non-invasive pressure ventilation or high flow oxygen devices (category 4); hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO (category 5); death (category 6).
Measure: Time to Improvement of at Least 2 Categories Relative to Baseline on the 6-Point Ordinal Clinical Recovery Scale Time: Up to Day 28Description: Percentage of participants with an improvement of at Least 2 categories relative to baseline on the 6-point ordinal clinical recovery scale on Day 28 will be reported.
Measure: Percentage of Participants with an Improvement of at Least 2 Categories Relative to Baseline on the 6-Point Ordinal Clinical Recovery Scale on Day 28 Time: Day 28Description: Percentage of participants with all-cause mortality will be reported.
Measure: Percentage of Participants with All-cause Mortality Time: Up to Day 28Description: A SAE is any adverse event (AE) that results in: death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect and is a suspected transmission of any infectious agent via a medicinal product, is medically important.
Measure: Percentage of Participants with Serious Adverse Events (SAEs) Time: Up to Day 28Description: An AE is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product.
Measure: Percentage of Participants with Related Adverse Events Time: Up to Day 28Description: Percentage of participants with severe or life-threatening, bacterial, invasive fungal, viral or opportunistic infections (other than severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2]) will be reported.
Measure: Percentage of Participants with Severe or Life Threatening Bacterial, Invasive Fungal, Viral or Opportunistic Infections Time: Up to Day 28Description: Percentage of participants with grade 3 (severe) or 4 (life-threatening) neutropenia will be reported.
Measure: Percentage of Participants with Grade 3 and 4 Neutropenia Time: Up to Day 28Description: Percentage of participants with grade 3 (severe) or 4 (life-threatening) lymphocytopenia will be reported.
Measure: Percentage of Participants with Grade 3 and 4 Lymphocytopenia Time: Up to Day 28Description: Percentage of participants with increased ALT >=3 times ULN combined with increased bilirubin >2 times ULN (up to Day 28) will be reported.
Measure: Percentage of Participants with Increased Alanine Aminotransferase (ALT) Greater than or equal to 3 Times Upper Limit of Normal (ULN) Combined with Increased Bilirubin > 2 Times ULN Time: Up to Day 28Description: Time to improvement of at least 1 category relative to baseline on the 6-point ordinal clinical recovery scale will be reported.
Measure: Time to Improvement of at least 1 Category Relative to Baseline on the 6-Point Ordinal Clinical Recovery Scale Time: Up to Day 28Description: Percentage of participants with an improvement of at Least 1 category relative to baseline on the 6-point ordinal clinical recovery scale on Day 28 will be reported.
Measure: Percentage of Participants with an Improvement of at Least 1 Category Relative to Baseline on the 6-Point Ordinal Clinical Recovery Scale on Day 28 Time: Day 28Description: Time from study intervention to end of oxygen supplementation is defined as achieving category 1 or 2 on the 6-point ordinal clinical recovery scale.
Measure: Time from Study Intervention to end of Oxygen Supplementation Time: Up to Day 28Description: Time from study intervention to hospital discharge among the surviving participants will be reported.
Measure: Time from Study Intervention to Hospital Discharge Among the Surviving Participants Time: Up to Day 28Description: Total length of hospitalization (days from admission to hospital discharge) among the surviving participants will be reported.
Measure: Total Length of Hospitalization Time: Up to Day 28Description: Number of Ventilation free Days will be reported.
Measure: Number of Ventilation Free Days Time: Up to Day 28Description: Participant's clinical status at Day 7, 14, 21, 28 will be assessed by 6-point ordinal clinical recovery scale.
Measure: Participant's Clinical Status at Day 7, 14, 21, 28 as Assessed by 6-Point Ordinal Clinical Recovery Scale Time: Day 7, 14, 21, 28Description: Total time on invasive mechanical ventilation will be reported.
Measure: Total Time on Invasive Mechanical Ventilation Time: Up to Day 28Description: Percentage of participants with a worsening of at least 1 category on the 6-point ordinal clinical recovery scale over time (between Day 5 and Day 28) will be reported.
Measure: Percentage of Participants with a Worse Category Relative to Baseline on the 6-Point Ordinal Clinical Recovery Scale over Time Time: From Day 5 up to Day 28Description: Percentage participants on ECMO over time will be reported.
Measure: Percentage of Participants on Extracorporeal Membrane Oxygenation (ECMO) Over Time Time: Up to Day 28Description: Total time on ECMO will be reported.
Measure: Total Time on ECMO Time: Up to Day 28Description: Percentage of alive participants at Day 28, Week 8 and Week 16 will be reported.
Measure: Percentage of Alive Participants at Day 28, Week 8 and Week 16 Time: Day 28, Week 8 and Week 16Description: Percentage of alive participants that required readmission (if previously discharged) at Week 8 and Week 16 will be reported.
Measure: Percentage of Alive Participants that Required Readmission at Week 8 and Week 16 Time: Week 8 and Week 16Description: A SAE is any adverse event (AE) that results in: death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect and is a suspected transmission of any infectious agent via a medicinal product, is medically important.
Measure: Percentage of Participants with Serious Adverse Events (SAEs) Time: Up to Week 16Pharmacological therapies of proven efficacy in coronavirus disease 2019 (COVID-19) are still lacking. Since two clinical stages of COVID-19 are emerging, an early one with typical clinical characteristics of a viral infection (fever, malaise, cough) and a later one with pneumonia leading to progressive respiratory failure, associated with heavy, cytokine-mediated, inflammation, an intervention by a compound possessing both antiviral activity and immunomodulatory effects would be most effective at the earliest possible stage. The purpose of this clinical trial is to test the efficacy of Interferon-β-1a (IFNβ-1a), in COVID-19 patients in an open label, randomized clinical trial. The design of the study is to test IFNβ-1a in addition to standard of care compared with standard of care alone. The primary outcome is the time to negative conversion of Severe Acute Respiratory Syndrome-CoronaVirus-2 (SARS-CoV-2) nasopharyngeal swabs.
Description: Viral load will be measured by Real Time-Polymerase Chain Reaction (RT-PCR)
Measure: Time to negative conversion of SARS-CoV-2 nasopharyngeal swab Time: From baseline to day 29Description: Defined as percentage of patients reporting each severity rating on a 7-point ordinal scale
Measure: Improvement in clinical severity score (a) Time: Baseline, days 7, 15, 21, 29Description: Defined as the time to clinical improvement of two points from the time of randomization on a 7-category ordinal scale or live discharge from the hospital, whichever comes first
Measure: Improvement in clinical severity score (b) Time: Baseline, days 7, 15, 21, 29Description: Measured with artificial intelligence and expressed as cc and percent values of diseased lung (lung consolidation, ground glass opacities and disease free)
Measure: Changes from baseline in pulmonary computed tomography (CT) imaging severity score Time: Baseline, day 21; extra follow up at 90 daysThe purpose of this study is to evaluate whether rivaroxaban reduces the risk of a composite endpoint of major venous and arterial thrombotic events, all-cause hospitalization, and all-cause mortality compared with placebo in outpatients with acute, symptomatic Coronavirus Disease 2019 (COVID-19) Infection.
Description: Time to first occurrence of a composite endpoint of symptomatic venous thromboembolism (VTE), myocardial infarction (MI), ischemic stroke, acute limb ischemia, noncentral nervous system (non-CNS) systemic embolization, all-cause hospitalization, and all-cause mortality will be assessed.
Measure: Time to First Occurrence of a Composite Endpoint of Symptomatic VTE, MI, Ischemic Stroke, Acute Limb Ischemia, Non-CNS Systemic Embolization, All-cause Hospitalization and All-cause Mortality Time: Up to Day 35Description: Time to first occurrence of a composite endpoint of symptomatic VTE, MI, ischemic stroke, acute limb ischemia, non-CNS systemic embolization, and all-cause mortality will be assessed.
Measure: Time to First Occurrence of a Composite Endpoint of Symptomatic VTE, MI, Ischemic Stroke, Acute Limb Ischemia, Non-CNS Systemic Embolization, and All-cause Mortality Time: Up to Day 35Description: Time to first occurrence of all-cause hospitalization will be assessed.
Measure: Time to First Occurrence of All-cause Hospitalization Time: Up to Day 35Description: Time to first occurrence of symptomatic VTE which includes DVT or pulmonary embolism (PE) will be assessed.
Measure: Time to First Occurrence of Symptomatic VTE Time: Up to Day 35Description: Time to first occurrence of an ER visit will be assessed.
Measure: Time to First Occurrence of an Emergency Room (ER) Visit Time: Up to Day 35Description: Time to first occurrence of symptomatic VTE, MI, ischemic stroke, acute limb ischemia, non-CNS systemic embolization, and all-cause hospitalization will be assessed.
Measure: Time to First Occurrence of Symptomatic VTE, MI, Ischemic Stroke, Acute Limb Ischemia, Non-CNS Systemic Embolization, and All-cause Hospitalization Time: Up to Day 35Description: Percentage of participants who are hospitalized or dead from any cause at Day 35 will be assessed.
Measure: Percentage of Participants who are Hospitalized or Dead From Any Cause Time: Day 35Description: Time to all-cause mortality up to Day 35 will be assessed.
Measure: Time to All-cause Mortality up to Day 35 Time: Up to Day 35Description: Time to first occurrence of ISTH critical site and fatal bleeding will be assessed.
Measure: Time to First Occurrence of International Society on Thrombosis and Hemostasis (ISTH) Critical Site and Fatal Bleeding Time: Up to 37 Days (last dose on Day 35 plus 2 Days)Description: Time to first occurrence of ISTH major bleeding will be assessed. Major bleeding is defined as clinically overt bleeding that is associated with a reduction in hemoglobin of 2 gram per deciliter (g/dL) or more, or a transfusion of 2 or more units of packed red blood cells or whole blood, or occurrence at a critical site defined as intracranial, intra-spinal, intraocular, pericardial, intra-articular, intra-muscular with compartment syndrome, retroperitoneal, or fatal outcome.
Measure: Time to First Occurrence of ISTH Major Bleeding Events Time: Up to 37 Days (last dose on Day 35 plus 2 Days)Description: Time to first occurrence of clinically relevant non-major bleeding will be assessed. Clinically relevant non-major bleeding is defined as overt bleeding not meeting the criteria for major bleeding but associated with medical intervention, or unscheduled contact with a physician, or temporary cessation of study treatment, or discomfort such as pain, or impairment of activities of daily life.
Measure: Time to First Occurrence of Clinically Relevant Non-major Bleeding Time: Up to 37 Days (last dose on Day 35 plus 2 Days)The clinical trial will evaluate the short term and extended impact on on respiration, pulmonary function and cardiovascular function in C2Rx treatment verse Standard of Care (SOC) in critically ill adults with COVID-19 infections .
Description: Change in patient Arterial Oxygen Partial Pressure (PaO2)/Fractional Inspired Oxygen (FiO2) Ratio
Measure: Pulmonary Oxygenation Function Time: Up to 72 hoursDescription: Change in patient oxygenation
Measure: Pulmonary Compliance of Respiratory System (CRS) Time: Up to 96 hoursDescription: Change in the total number of patients that survived
Measure: Survival Time: 30 days and 60 daysDescription: Change in Hospital Utilization of ventilators (days)
Measure: Hospital Costs 1 Time: Out to 60 daysDescription: Change in score based on the calculation of the following medications used: dopamine dose (µg/kg/min) + dobutamine dose (µg/kg/min) + 100 x adrenaline dose (µg/kg/min) + 100 x noradrenaline dose (µg/kg/min) + 10 x milrinone dose (µg/kg/min) + 10.000 x vasopressin dose (U/kg/min)
Measure: Cardiovascular Vasoactive-Inotropic Score (VIS) Time: Up to 96 hoursDescription: Change in Hospital Utilization of vasopressor medication (days without use)
Measure: Hospital Costs 2 Time: Out to 60 daysDescription: Change in Hospital Utilization of Intensive Care Unit (ICU) Hospital free days
Measure: Hospital Costs 3 Time: Out to 60 daysDescription: Change in Hospital Utilization of Renal Replacement Therapy (days on therapy)
Measure: Hospital Costs 4 Time: Out to 60 daysDescription: Change in Hospital Utilization (days hospitalized)
Measure: Hospital Costs 5 Time: Out to 60 daysDescription: Changes in inflammatory mediators detected by Immunoassay of Multianalyte Panel - MAP Laboratory Panel of 253 analytes.
Measure: Inflammatory mediators in blood Time: Out to 14 hoursDescription: Change in cytokine levels obtained from plasma and blood collected prior to and after filter. Analyte concentrations in ultrafiltrate and plasma, expressed in the same concentration units, will be aggregated as a ratio of ultrafiltrate concentration to plasma concentration to yield a unitless Sieving Coefficient (SC). SC is an index of membrane function.
Measure: Cytokine Sieving Effects Time: Out to 8 hoursDescription: Change in blood Ferritin (mg/mL)
Measure: Specific Blood Indicators 1 Time: Out to 14 hoursDescription: Change in blood Interleukin-6 (pg/mL)
Measure: Specific Blood Indicators 2 Time: Out to 14 hoursDescription: Change in blood C-reactive protein (CRP) (mg/L)
Measure: Specific Blood Indicators 3 Time: Out to 14 hoursDescription: Change in blood Lactate Dehydrogenase (LDH) (U/L)
Measure: Specific Blood Indicators 4 Time: Out to 14 hoursDescription: Change in blood D-dimer (mcg/L*FEU2)
Measure: Specific Blood Indicators 5 Time: Out to 14 hoursDescription: Change in blood White Blood Cell (WBC) count (%)
Measure: Specific Blood Indicators 6 Time: Out to 14 hoursDescription: Change in blood Neutrophil count (%)
Measure: Specific Blood Indicators 7 Time: Out to 14 hoursDescription: Change in blood lymphocyte count (%).
Measure: Specific Blood Indicators 8 Time: Out to 14 hoursDescription: Change in the duration of days of diagnosed HAI/ Sepsis infections
Measure: Hospital Acquired Infections (HAI) /Sepsis Time: 30 and 60 daysDescription: Duration without Respiratory Replacement Therapy (RRT), ventilator, and time to discharge
Measure: Composite Recovery Time: Up to 30 daysDescription: Survival without Respiratory Replacement Therapy (RRT), ventilator, or time to Long Term Care (LTC)
Measure: Composite Survival Time: 30 and 60 daysDescription: Survival with Respiratory Replacement Therapy (RRT), ventilator or in Long Term Care (LTC)
Measure: Composite Non-Recovery Time: Up to 60 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports